Barclays analyst Gena Wang maintains Overweight on Sarepta Therapeutics (NASDAQ: SRPT) price target of $180.00.The analyst says ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE